Revance Therapeutics, Inc. is a privately held biopharmaceutical company developing products that will change the way that drugs are delivered. The company's lead investigational product is a topically applied botulinum toxin type A (BoNTA) with a broad pipeline of indications. It has the potential to provide a painless alternative to treatment with one of the world's most recognized drugs.